Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 11/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487979 | 0.66 | POLB (0.36) | — | |
| SCHEMBL6332549 | 0.66 | HRH3 (0.39) | KDM1AHRH3MAOA | |
| SCHEMBL6332552 | 0.66 | HRH3 (0.39) | KDM1AHRH3MAOA | |
| SCHEMBL7661587 | 0.65 | P2RX7 (0.70) | — | |
| SCHEMBL6532214 | 0.63 | HRH3 (0.36) | KDM1AHRH3 | |
| Piperazine SCHEMBL27572562 | 0.62 | ALDH1A1 (0.34) | — | |
| SCHEMBL214697 | 0.62 | KDM1A (0.42) | KDM1AWNT1GSK3BDYRK1AMAOA | |
| SCHEMBL214698 | 0.62 | KMT2A (0.46) | KDM1A | |
| SCHEMBL6476996 | 0.61 | OPRK1 (0.59) | DYRK1A | |
| SCHEMBL6478290 | 0.60 | OPRK1 (0.61) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | CYP3A5, IL5, ABCC5 | KDM1A 1113/4885HRH3 1123/4885IGF1R 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.